Physician profile
Robert James Norman
NPI 1407168610
$671.07
in general payments reported to CMS, 2019-2025
12 companies · $45.62 in 2025
The $45.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $138 · 2021: $57.65 · 2023: $31.56 · 2024: $79.88 · 2025: $45.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $407.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $48.43 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.69 | 2019 | |
| Galderma Laboratories, L.P. | $35.43 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $27.01 | 2019 | |
| Glaxosmithkline, LLC. | $25.82 | 2019-2021 | |
| Pfizer INC. | $16.29 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.69 | 2019 | |
| Insulet Corporation | $14.90 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $13.04 | 2019 | |
| Lilly USA, LLC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.